title: Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications.
abstract: The prognostic significance of the clinical presentation of atrial fibrillation (AF) is poorly defined.
  
  
  
  The purpose of this study was to determine the frequency, associations, and prognostic impact of different clinical presentations of new-onset AF.
  
  
  
  One thousand patients with incident AF in Olmsted County, Minnesota, were randomly selected (2000-2010). Patients with AF that was complicated at presentation (heart failure [n = 71], thromboembolism [n = 24]), provoked (n = 346), or unable to determine symptoms (n = 83) were excluded. In the remaining patients, characteristics and prognosis associated with different types of symptoms were examined.
  
  
  
  Among 476 patients, 193 had typical (palpitations), 122 had atypical (other non-palpitation symptoms), and 161 had asymptomatic AF presentation. Patients with typical presentation had lower CHA2DS2-VASc scores (mean 2.3 ± 2) compared to atypical and asymptomatic presentation (mean 3.2 ± 1.8 and 3.3 ± 1.9, respectively; P <.001). Fifty-nine cerebrovascular events and 149 deaths (n = 49 cardiovascular) were documented over median 5.6 and 6.0 years, respectively. Atypical and asymptomatic AF conferred higher risks of cerebrovascular events compared to typical AF after adjustment for CHA2DS2-VASc score and age (hazard ratio [HR] 3.51, 95% confidence interval [CI] 1.65-7.48, and HR 2.70, 95% CI 1.29-5.66, respectively), and associations remained statistically significant after further adjustments including comorbidities and warfarin use. Asymptomatic AF was associated with an increased risk of cardiovascular (HR 3.12, 95% CI 1.50-6.45) and all-cause mortality (HR 2.96, 95% CI 1.89-4.64) compared to typical AF after adjustment for CHA2DS2-VASc score and age.
  
  
  
  The type of clinical presentation may have important implications for the prognosis of new-onset AF in the community.
authors.affiliation: Department of Medicine, Mayo Clinic, Rochester, Minnesota; Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan.
authors.forename: Konstantinos C
authors.initials: KC
authors.lastname: Siontis
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Gersh
authors.affiliation: Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
authors.forename: Jill M
authors.initials: JM
authors.lastname: Killian
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Noseworthy
authors.affiliation: Department of Nursing Administration, Mayo Clinic, Rochester, Minnesota.
authors.forename: Pamela
authors.initials: P
authors.lastname: McCabe
authors.affiliation: Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
authors.forename: Susan A
authors.initials: SA
authors.lastname: Weston
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
authors.forename: Veronique L
authors.initials: VL
authors.lastname: Roger
authors.affiliation: Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Electronic address: chamberlain.alanna@mayo.edu.
authors.forename: Alanna M
authors.initials: AM
authors.lastname: Chamberlain
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D058070:Asymptomatic Diseases / Q000453:epidemiology; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011897:Random Allocation; D018570:Risk Assessment / Q000379:methods; D016019:Survival Analysis; D063189:Symptom Assessment / Q000379:methods / Q000706:statistics & numerical data; D013923:Thromboembolism / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D014481:United States / Q000453:epidemiology; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin
keywords: Atral fibrillation; Clinical presentation; Palpitations; Prognosis; Stroke